Surgery Debate for Asymptomatic Carotid Blockages: A New Perspective
Should we operate on blocked carotid arteries if patients show no symptoms? This question has sparked a significant debate among cardiologists and vascular specialists, and a large-scale trial has just added fuel to the fire.
The CREST-2 Trial Findings:
Cardiology > Atherosclerosis
In the realm of carotid artery disease, a recent study, CREST-2, has revealed intriguing results. The trial focused on patients with high-grade carotid stenosis, a condition where the carotid arteries, which supply blood to the brain, become significantly narrowed.
- Stenting vs. Endarterectomy: Carotid-artery stenting and endarterectomy are common procedures for treating carotid stenosis. However, the study found that stenting provided a slight advantage in stroke and death prevention over medical management alone in asymptomatic patients.
- Endarterectomy's Role: Interestingly, endarterectomy, a surgical procedure to remove plaque from the artery, did not show a significant benefit over medical management in preventing strokes or reducing mortality.
Unlocking the Results:
- The study's primary endpoint, which included any stroke or death within 44 days or ipsilateral ischemic stroke within 4 years, occurred in 2.8% of patients with stenting compared to 6.0% with medical therapy alone. This difference was statistically significant (P=0.02).
- Endarterectomy had a stroke/death rate of 3.7%, not significantly different from medical therapy (5.3%, P=0.24).
Expert Opinions:
An accompanying editorial by renowned experts Dr. Martin Brown and Dr. Leo Bonati suggests that routine endarterectomy for asymptomatic patients is no longer necessary. But here's where it gets controversial—they also caution against widespread adoption of stenting for these cases.
Historical Context:
Decades ago, surgery was the go-to option for carotid stenosis. However, with advancements in medical therapy, the balance between surgical intervention and medication has become a hot topic. The previous CREST trial and the SPACE-2 trial had similar findings, showing no significant advantage to revascularization over medical management.
The Fine Print:
Despite the positive results for stenting, the editorialists highlight a few crucial points:
- The benefit of revascularization for asymptomatic stenosis is now small due to improved medical treatments.
- The trial's patients were carefully selected and treated by skilled professionals, which may not reflect real-world scenarios.
- Medical therapy had room for improvement, with many patients not meeting optimal blood pressure and cholesterol targets.
A Pragmatic Approach:
The editorialists propose a practical strategy: advising asymptomatic patients to start intensive medical therapy immediately and delay surgery until symptoms appear, which is rare. Stenting could be an option for those who prefer it or cannot tolerate medication.
Trial Details:
CREST-2 was a comprehensive study with two parallel trials, involving patients from multiple countries. Serious complications were rare with both procedures, but the trial had limitations, including its single-blind design and the lack of newer medical advancements.
Personalized Medicine:
Dr. Thomas Brott emphasizes the importance of personalized decision-making. Stenting might be more suitable for patients with higher-grade stenosis or unstable plaque. Future trials should focus on identifying these high-risk patients who might benefit from early intervention.
And this is the part most people miss—the study highlights the need for a tailored approach, considering each patient's unique condition and preferences. Should we let the data guide our decisions or rely on clinical judgment? What's your take on this complex issue? Share your thoughts below!
